News
Lilly gets approval for earlier use of Jaypirca in CLL
Eli Lilly's fast-growing Jaypirca has won a new FDA approval as an earlier treatment for relapsed/refractory chronic lymphocytic leukaemia.
Oncology
ESMO 2025 in review: A new era in oncology, from AI to next-...
ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.
News
Appeals court turns Enhertu patent dispute on its head
A US appeals court has reversed a 2023 decision that ordered Daiichi Sankyo to pay royalties on sales of cancer drug Enhertu to Seagen (now Pfizer).
Oncology
Delving into the physics of cancer, with Lew Bender
In a new podcast, Intensity Therapeutics' Lew Bender discusses intra-tumourally injected therapeutics - a novel approach to cancer cell death.
News
Pazdur to leave FDA, shortly after taking CDER job
Long-serving FDA figure Richard Pazdur has filed papers to retire, shortly after being appointed to lead CDER, according to reports.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
